Moreover, a phase II study of nitric oxide donors for men with increasing prostate-specific antigen levels after surgery or radiotherapy for prostate cancer demonstrated that nitric oxide attenuates hypoxia-induced progression of prostate cancer [102]. Here, KLK3 is linked to prostate carcinoma.